Latest Myopia News

HOYA Presents Six-Year MiYOSMART Data at EAOO Conference

May 16, 2022

DUBLIN — HOYA Vision Care presented the findings from its six-year clinical trial on the MiYOSMART lenses at the European Academy of Optometry and Optics (EAOO) conference in Dublin, Ireland. The study focused on HOYA’s Defocus Incorporated Multiple Segments (D.I.M.S.) technology, and the findings were shared by Professor Carly Lam from the Center for Myopia Research at The Hong Kong Polytechnic University.

The results of the six-year clinical study conducted on 90 children in Asia looked at the progression of myopia in children who wore the HOYA Vision Care’s MiYOSMART spectacle lens. The results
enhanced a previous three-year follow-up study,1 a continuation of a two-year randomized controlled trial (RCT),2 demonstrating strong evidence of the lenses’ effectiveness in slowing down the progression of myopia in children ages 8-13. The findings of the six-year, long-term follow-up clinical study proved the MiYOSMART spectacle lens myopia control effect is sustained over time for children wearing the lens. It also confirmed that patients who stop wearing the MiYOSMART spectacle lens show no rebound effect when compared to the initial myopia rates of progression during the two-year randomized controlled trial or with the general population.3

“We are proud to share our six-year clinical study on the MiYOSMART lens, the longest study
conducted on a myopia management spectacle lens ever with this European audience of eye care
professionals. The study importantly shows that the myopia control effect is sustainable over time
which is very exciting news,” said Natalia Vlasak, ophthalmologist, Global Head of Medical and
Scientific Affairs at HOYA Vision Care. “This study also answered another key question from eye
care professionals which was about the rebound effect of the lens — we are very pleased that this clinical study proves that there is no rebound effect if lens use is stopped. HOYA Vision Care is
dedicated to being a leader in developing a safe, effective way to manage the growing problem of
myopia in children.”


1 Lam CS, Tang WC, Lee PH, et al. Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. British Journal of Ophthalmology Published Online First: 17 March 2021. doi: 10.1136/bjophthalmol-2020-317664

2 Lam CSY, Tang WC, Zhang A, Tse D, To CH. Myopia control in children wearing DIMS spectacle lens: 6 years results. The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting, May 1-4, Denver, US.

3 Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomized clinical trial. British Journal of Ophthalmology. Published Online First: 29 May 2019. doi: 10.1136/bjophthalmol-2018-313739

PRODUCT DISCLAIMER — MiYOSMART has not been approved for myopia management in all countries, including the U.S., and is not currently available for sale in all countries, including the U.S.

To Top